Cargando…

HGG-31. Unique case of a bithalamic H3K27-wildtype diffuse midline glioma, EGFR-altered with methylated MGMT

BACKGROUND: Diffuse midline gliomas are aggressive pediatric brain tumors frequently associated with somatic mutations in histone genes H3F3A (H3.3) and HIST1H3B (H3.1), which promote gliomagenesis through reprograming of the epigenetic landscape by inhibiting the tri-methylation of H3K27 (H3K27-me3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reinecke, James, Cottrell, Catherine, Rush, Sarah, Judd, Alexis, Palmer, Joshua, Pierson, Christopher, Lazow, Margot, Wilson, Yelena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	High Grade Glioma
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165181/ http://dx.doi.org/10.1093/neuonc/noac079.246

Ejemplares similares

HGG-03. PEDIATRIC BITHALAMIC GLIOMA H3K27M NEGATIVE AND EGFR POSITIVE: A DISTINCT ENTITY WITH POTENTIAL SENSIBILITY TO EGFR INHIBITORS
por: Hernandez, Marta Cortes, et al.
Publicado: (2022)

HGG-24. NTRK-rearranged infantile gliomas of suprasellar/ optic pathway origin
por: Lazow, Margot A, et al.
Publicado: (2022)

HGG-56. EXTENSIVE MOLECULAR HETEROGENEITY WITHIN H3-/IDH-WILDTYPE PEDIATRIC GLIOBLASTOMA
por: Blattner-Johnson, Mirjam, et al.
Publicado: (2020)

HGG-50. TWO CASES OF H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA OF CERVICAL SPINAL CORD
por: Kuroha, Masae, et al.
Publicado: (2020)

HGG-03. THE GLYCOSPHINGOLIPIDS METABOLISM IS A NOVEL TARGET IN H3K27M-MUTANT DIFFUSE MIDLINE GLIOMA
por: Paret, Claudia, et al.
Publicado: (2021)

HGG-33. Prognostic factors of H3K27M histone-mutant diffuse midline gliomas in patients ≤18yrs
por: Hu, Qingjun, et al.
Publicado: (2022)

HGG-08. CREATION OF AN IN VITRO AND IN VIVO MODEL SYSTEM FOR THE STUDY OF H3.1K27M DIPG
por: Lagas, Joseph, et al.
Publicado: (2021)

HGG-31. UNIQUE BIOLOGICAL CHARACTERISTICS OF RADIATION-INDUCED GLIOMAS
por: Váňová, Kateřina, et al.
Publicado: (2020)

HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG)
por: Cosentino, Chiara Cianciolo, et al.
Publicado: (2021)

HGG-45. Characterization of spinal diffuse midline gliomas, H3 K28M-mutant
por: Stegat, Lotte, et al.
Publicado: (2022)

HGG-35. IDENTIFICATION OF G PROTEIN-COUPLED RECEPTOR 17 (GPR17) UP-REGULATION IN PAEDIATRIC H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA AND EXAMINATION OF ITS ROLE IN DIFFUSE MIDLINE GLIOMA CELL LINES
por: Loveson, Katie, et al.
Publicado: (2021)

HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS
por: Mueller, Timothy, et al.
Publicado: (2021)

HGG-38. DE NOVO PYRIMIDINE SYNTHESIS INHIBITION INDUCES REPLICATION CATASTROPHE MEDIATED CELL DEATH IN DIFFUSE MIDLINE GLIOMA
por: Pal, Sharmistha, et al.
Publicado: (2021)

HGG-27. ANTI-CANCER POTENTIAL OF ARGINASE FOR HIGH-GRADE GLIOMA IN VITRO & IN-VIVO
por: Fung, M K L, et al.
Publicado: (2020)

HGG-27. HNRNPA1 SPLICED VARIANT SENSITIZATION EFFECT DISCLOSED IN GLIOMA CELLS
por: Yadav, Ajay
Publicado: (2021)

HGG-27. Understanding the role of PLAG family transcription factors in cortex development and tumorigenesis
por: Vaillant, Jan, et al.
Publicado: (2022)

HGG-18. CLINICAL EFFICACY OF ONC201 IN THALAMIC H3 K27M-MUTANT GLIOMA
por: Kawakibi, Abed Rahman, et al.
Publicado: (2020)

HGG-36. ONC201 TARGETING IN DIPG
por: Abuarqoub, Alqassem, et al.
Publicado: (2021)

HGG-43. INTERROGATING THE ROLE OF PEA3 ONCOGENIC TRANSCRIPTION FACTORS IN PEDIATRIC HIGH-GRADE K27M GLIOMAS
por: Park, Hannah, et al.
Publicado: (2021)

HGG-29. How I treat recurrent pediatric high-grade glioma (HGG): A Europe-wide survey study.
por: Perwein, Thomas, et al.
Publicado: (2022)

HGG-58. SIOPE HGG Working Group approach to obtain consensus on management of paediatric high grade glioma across Europe
por: Giraud, Géraldine, et al.
Publicado: (2022)

HGG-44. REVEALING VULNERABILITIES IN DIPG THROUGH ONC201
por: Stafford, James, et al.
Publicado: (2021)

HGG-33. EXPLOITING METABOLIC DEFECTS WITH NAMPT INHIBITORS IN DIPG
por: Muraleedharan, Ranjithmenon, et al.
Publicado: (2021)

HGG-09. FIRST LINE THERAPY OF PEDIATRIC GLIOBLASTOMA WITH LAROTRECTINIB
por: Alharbi, Musa, et al.
Publicado: (2020)

HGG-31. HISTONE H3.3 G34R/V MUTATIONS STIMULATE PEDIATRIC HIGH-GRADE GLIOMA FORMATION THROUGH THE INDUCTION OF CHROMOSOMAL INSTABILITY
por: Grigore, Florina, et al.
Publicado: (2021)

HGG-12. HUMAN IPSC-DERIVED H3.3K27M NEUROSPHERES: A NOVEL MODEL FOR INVESTIGATING DIPG PATHOGENESIS AND DRUG RESPONSE
por: Skinner, Kasey, et al.
Publicado: (2021)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

HGG-21. MALIGNANT SYNAPTIC PLASTICITY IN PEDIATRIC HIGH-GRADE GLIOMAS
por: Taylor, Kathryn, et al.
Publicado: (2021)

HGG-32. UNCOVERING THERAPEUTIC VULNERABILITIES IN MISMATCH REPAIR-DEFICIENT GLIOMAS
por: Boynton, Adam, et al.
Publicado: (2020)

HGG-41. STRUCTURAL VARIANT DRIVERS IN PEDIATRIC HIGH-GRADE GLIOMA
por: Dubois, Frank, et al.
Publicado: (2020)

HGG-56. Spatial mapping of the tumor micro-environment in pediatric glioma
por: Messiaen, Julie, et al.
Publicado: (2022)

HGG-51. Uncovering therapeutic vulnerabilities in mismatch repair-deficient gliomas
por: Boynton, Adam, et al.
Publicado: (2022)

HGG-22. Uptake of investigational therapy in children with High Grade Glioma
por: Toledano, Helen, et al.
Publicado: (2022)

HGG-42. PEDIATRIC H3K27M MUTANT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) SHOWS ROBUST RESPONSE TO IMIPRIDONE BASED COMBINATION THERAPY
por: Borsuk, Robyn, et al.
Publicado: (2021)

HGG-34. DETECTION OF ONCOGENIC FUSION EVENTS IN SUPRATENTORIAL GLIOBLASTOMAS OF YOUNG CHILDREN
por: Pietsch, Torsten, et al.
Publicado: (2020)

HGG-42. CLINICAL FEATURES AND TREATMENT OUTCOME OF MALIGNANT GLIOMAS IN CHILDREN AND ADOLESCENTS
por: Yonezawa, Hajime, et al.
Publicado: (2020)

HGG-16. EXOSOME-MEDIATED INTER-CLONAL INTERACTIONS IN PEDIATRIC GBM AND DIPG
por: Pericoli, Giulia, et al.
Publicado: (2020)

HGG-41. CHARACTERIZATION OF THE IMMUNE RESPONSE FOLLOWING VARIOUS RADIOTHERAPY TREATMENTS IN GLIOBLASTOMA
por: Cocito, Carolina, et al.
Publicado: (2021)

HGG-44. DEFECTS OF MISMATCH REPAIR PROTEINS IN PEDIATRIC HIGH GRADE GLIOMAS
por: Haberler, Christine, et al.
Publicado: (2020)

HGG-40. NF1 mosaicism in a CMMRD-patient with a glioblastoma
por: Guerrini-Rousseau, Lea, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rg9btjaidokalrtup8tbmij3um